Investigational Drug Details
| Drug ID: | D134 |
| Drug Name: | Fenretinide |
| Synonyms: | 4-HPR; 4-hydroxy(phenyl)retinamide; 4-hydroxyphenyl retinamide; Fenretinide; N-(4-hydroxyphenyl)all-trans retinamide |
| Type: | Chemical drug |
| DrugBank ID: | DB05076 |
| DrugBank Description: | A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent. |
| PubChem ID: | 5288209 |
| CasNo: | 65646-68-6 |
| Repositioning for NAFLD: | No |
| SMILES: | C(=C\C(=C\C=C\C(=C\C(=O)Nc1ccc(cc1)O)\C)\C)/C1=C(C)CCCC1(C)C |
| Structure: |
|
| InChiKey: | AKJHMTWEGVYYSE-FXILSDISSA-N |
| Molecular Weight: | 391.555 |
| DrugBank Targets: | -- |
| DrugBank MoA: | Fenretinide inhibits the growth of several human cancer cell lines, acting through both retinoid-receptor-dependent and retinoid-receptor-independent mechanisms.1In vivo, fenretinide selectively accumulates in breast tissue and is particularly active in inhibiting rat mammary carcinogenesis.1 An important feature of fenretinide is its ability to inhibit cell growth through the induction of apoptosis rather than through differentiation, an effect that is strikingly different from that of vitamin A.1 In contrast to tamoxifen, which inhibits only estrogen receptor (ER)-positive tumors, fenretinide induces apoptosis in both ER-positive and ER-negative breast cancer cell lines.2 All of these properties render fenretinide an attractive candidate for breast cancer chemoprevention. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | Investigated for use/treatment in macular degeneration. |
| Targets: | RARB agonist; RARG agonist |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | Phase 2 suspended (NCT00546455: This study was terminated due to expired drug with possibility of re-starting in the future.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0978 | NCT00546455 | Phase 2 | Recruiting | No Results Available | 17/10/2007 | 19 February 2015 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |